Research programme: gene therapy - Spark Therapeutics Ireland

Drug Profile

Research programme: gene therapy - Spark Therapeutics Ireland

Alternative Names: GT 038; RHO-adRP; RhoNova; SPK- LHON

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Genable Technologies
  • Developer Spark Therapeutics Ireland
  • Class Gene therapies
  • Mechanism of Action Gene transference; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinitis pigmentosa

Most Recent Events

  • 07 Mar 2016 Genable Technologies has been acquired by Spark Therapeutics
  • 31 Oct 2014 GT 038 receives Advanced Therapy Medicinal Product designation for Retinitis pigmentosa in European Union
  • 11 Sep 2014 Genable Technologies moves GT 038 from research to full development for Retinitis pigmentosa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top